Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $108.26 USD
Change Today +0.48 / 0.45%
Volume 342.6K
LGND On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Frankfurt
OTC US
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals (LGND) Snapshot

Open
$108.04
Previous Close
$107.78
Day High
$109.58
Day Low
$106.67
52 Week High
07/30/15 - $109.95
52 Week Low
10/9/14 - $41.99
Market Cap
2.1B
Average Volume 10 Days
285.4K
EPS TTM
$0.57
Shares Outstanding
19.7M
EX-Date
04/3/07
P/E TM
188.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for LIGAND PHARMACEUTICALS (LGND)

ligand pharmaceuticals (LGND) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals (LGND) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals (LGND) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals (LGND) Key Developments

Ligand Pharmaceuticals Seeks Acquisitions

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announced that it is investing its capital in non-P&L ways to leverage its portfolio and financial expansion and looking at royalty acquisitions.

Ligand Pharmaceuticals Incorporated Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 04:45 PM

Ligand Pharmaceuticals Incorporated Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 04:45 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: John L. Higgins, Chief Executive Officer and Executive Director.

Ligand Pharmaceuticals Incorporated Presents at CJS Securities 15th Annual New Ideas Summer Investor Conference, Jul-14-2015

Ligand Pharmaceuticals Incorporated Presents at CJS Securities 15th Annual New Ideas Summer Investor Conference, Jul-14-2015 . Venue: Metropolis Country Club, White Plains, New York, United States. Speakers: Matthew W. Foehr, President and Chief Operating Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGND:US $108.26 USD +0.48

LGND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.08
Allergan plc $331.15 USD +2.28
Johnson & Johnson $100.21 USD +0.37
Pfizer Inc $36.06 USD +0.33
Valeant Pharmaceuticals International Inc C$335.61 CAD +4.75
View Industry Companies
 

Industry Analysis

LGND

Industry Average

Valuation LGND Industry Range
Price/Earnings 100.0x
Price/Sales 33.6x
Price/Book 60.6x
Price/Cash Flow 199.3x
TEV/Sales 27.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS, please visit www.ligand.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.